These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 28210937)
1. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence. Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937 [TBL] [Abstract][Full Text] [Related]
2. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Li D; Yan D; Tang H; Zhou C; Fan J; Li S; Wang X; Xia J; Huang F; Qiu G; Peng Z Ann Surg Oncol; 2009 Dec; 16(12):3499-506. PubMed ID: 19672661 [TBL] [Abstract][Full Text] [Related]
3. The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung. Del Gobbo A; Vaira V; Guerini Rocco E; Palleschi A; Bulfamante G; Ricca D; Fiori S; Bosari S; Ferrero S J Thorac Oncol; 2014 Nov; 9(11):1656-61. PubMed ID: 25144243 [TBL] [Abstract][Full Text] [Related]
4. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms. Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors Associated with Outcomes in Small Bowel Neuroendocrine Tumors. Manguso N; Johnson J; Harit A; Nissen N; Mirocha J; Hendifar A; Amersi F Am Surg; 2017 Oct; 83(10):1174-1178. PubMed ID: 29391119 [TBL] [Abstract][Full Text] [Related]
6. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study. Shi H; Zhang Q; Han C; Zhen D; Lin R BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596 [TBL] [Abstract][Full Text] [Related]
7. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. Shi C; Gonzalez RS; Zhao Z; Koyama T; Cornish TC; Hande KR; Walker R; Sandler M; Berlin J; Liu EH Am J Clin Pathol; 2015 Mar; 143(3):398-404. PubMed ID: 25696798 [TBL] [Abstract][Full Text] [Related]
8. IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes. Del Gobbo A; Morotti A; Colombo AE; Vaira V; Ercoli G; Pesenti C; Bonaparte E; Guerini-Rocco E; Di Cristofori A; Locatelli M; Palleschi A; Ferrero S Med Oncol; 2017 Dec; 35(1):2. PubMed ID: 29209838 [TBL] [Abstract][Full Text] [Related]
9. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. Zaidi MY; Lopez-Aguiar AG; Dillhoff M; Beal E; Poultsides G; Makris E; Rocha F; Crown A; Idrees K; Marincola Smith P; Nathan H; Beems M; Abbott D; Barrett JR; Fields RC; Davidson J; Cardona K; Maithel SK JAMA Surg; 2019 Feb; 154(2):134-140. PubMed ID: 30383112 [TBL] [Abstract][Full Text] [Related]
12. Pancreastatin predicts survival in neuroendocrine tumors. Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611 [TBL] [Abstract][Full Text] [Related]
13. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma. Hao S; Smith TW; Chu PG; Liu Q; Ok CY; Woda BA; Lu D; Lin P; Wang SA; Dresser K; Rock KL; Jiang Z Arch Pathol Lab Med; 2011 Aug; 135(8):1032-6. PubMed ID: 21809995 [TBL] [Abstract][Full Text] [Related]
14. Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis. Fata CR; Gonzalez RS; Liu E; Cates JM; Shi C Am J Surg Pathol; 2017 Jan; 41(1):128-133. PubMed ID: 27684993 [TBL] [Abstract][Full Text] [Related]
15. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties. Kankava K; Maisonneuve P; Mangogna A; Centonze G; Cattaneo L; Prinzi N; Pusceddu S; Fazio N; Pisa E; Di Domenico S; Bertani E; Mazzaferro V; Albertelli M; Grillo F; Milione M J Neuroendocrinol; 2021 Aug; 33(8):e13000. PubMed ID: 34268808 [TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort. Bösch F; Bruewer K; D'Anastasi M; Ilhan H; Knoesel T; Pratschke S; Thomas M; Rentsch M; Guba M; Werner J; Angele MK Surgery; 2018 Nov; 164(5):1093-1099. PubMed ID: 30076029 [TBL] [Abstract][Full Text] [Related]
17. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279 [TBL] [Abstract][Full Text] [Related]
18. Surgical Management of Small Bowel Neuroendocrine Tumors: Specific Requirements and Their Impact on Staging and Prognosis. Pasquer A; Walter T; Hervieu V; Forestier J; Scoazec JY; Lombard-Bohas C; Poncet G Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S742-9. PubMed ID: 26014153 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features and prognostic validity of WHO grading classification of SI-NENs. Chen L; Zhou L; Zhang M; Shang L; Zhang P; Wang W; Fang C; Li J; Xu T; Tan H; Zhang P; Qiu M; Yu X; Jin K; Chen Y; Chen H; Lin R; Zhang Q; Shen L; Chen M; Li J; Li L; Chen J BMC Cancer; 2017 Aug; 17(1):521. PubMed ID: 28778195 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Relevance of p53 Overexpression in Gastrointestinal Stromal Tumors of the Small Intestine: Potential Implication for Adjuvant Treatment with Imatinib. Yoo C; Koh YW; Park YS; Ryu MH; Ryoo BY; Park HJ; Yook JH; Kim BS; Kang YK Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S362-9. PubMed ID: 25791792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]